BR100 Increased By (0.12%)
BR30 Increased By (0.53%)
KSE100 Increased By (0.32%)
KSE30 Increased By (0.42%)
AGHA 6.41 Increased By ▲ 0.09 (1.42%)
BECO 4.37 Increased By ▲ 0.10 (2.34%)
BML 63.00 Increased By ▲ 0.55 (0.88%)
BOP 31.50 Increased By ▲ 0.27 (0.86%)
CNERGY 11.69 Increased By ▲ 0.10 (0.86%)
CSIL 5.89 Increased By ▲ 0.17 (2.97%)
FCCL 60.84 Decreased By ▼ -0.70 (-1.14%)
FFL 14.72 Decreased By ▼ -0.30 (-2%)
FNEL 1.23 No Change ▼ 0.00 (0%)
KEL 6.33 Increased By ▲ 0.07 (1.12%)
KOSM 5.94 Increased By ▲ 0.38 (6.83%)
LOTCHEM 24.68 No Change ▼ 0.00 (0%)
MLCF 103.25 Decreased By ▼ -0.83 (-0.8%)
NBP 173.10 Decreased By ▼ -2.18 (-1.24%)
NCPL 52.25 Decreased By ▼ -0.52 (-0.99%)
NPL 54.10 Decreased By ▼ -0.02 (-0.04%)
OGDC 316.78 Increased By ▲ 3.39 (1.08%)
PACE 9.20 No Change ▼ 0.00 (0%)
PAEL 35.80 No Change ▼ 0.00 (0%)
PIBTL 13.62 Increased By ▲ 0.15 (1.11%)
PPL 226.60 Increased By ▲ 4.79 (2.16%)
PRL 80.50 Increased By ▲ 1.42 (1.8%)
PTC 46.99 Increased By ▲ 0.14 (0.3%)
SSGC 23.70 Decreased By ▼ -0.17 (-0.71%)
TBL 9.29 Decreased By ▼ -0.02 (-0.21%)
TELE 7.54 Increased By ▲ 0.15 (2.03%)
TPL 24.69 Decreased By ▼ -0.42 (-1.67%)
TPLP 12.87 Increased By ▲ 0.36 (2.88%)
TREET 26.35 Increased By ▲ 0.10 (0.38%)
TRG 53.38 Decreased By ▼ -0.06 (-0.11%)
World

EU requests inspection of Belgian vaccine plant

  • European Commission has branded the excuses "unacceptable" and has demanded transparency over its shipments of doses out of EU plants.
Published Updated
By

BRUSSELS: The European Commission has requested an inspection of a Belgian plant producing the AstraZeneca coronavirus vaccine, a Belgian official said Thursday.

Following reports that the inspection had already taken place, Belgium's Federal Agency for Medicines and Health Products denied this but confirmed it was planned.

Brussels is at loggerheads with AstraZeneca over shipments of its coronavirus vaccine, after the company said production issues would slow promised deliveries once approval is granted for use in the EU.

The firm has continued to supply the UK government in line with a separate contract, while warning that "glitches" in its EU plants will cause delays.

But the European Commission has branded the excuses "unacceptable" and has demanded transparency over its shipments of doses out of EU plants.

Brussels says its contract with AstraZeneca foresaw that the British plants would be part of the European supply chain and insists this be respected.

One of the EU plants, the Henogen/Novasep site in Seneffe, underwent a routine Belgian inspection earlier this month, agency spokeswoman Ann Eeckhout said.

"This inspection was carried out by the AFMHPS and had no particular link with the European Commission," she said.

"It is this inspection and its results that are followed up by regular contacts with the company (like all Covid-19 projects)," she said.

"In the meantime the European Commission has asked to organise an inspection of the production flow. This inspection has not yet taken place."

Belgian media reports late Wednesday had said that an inspection had already been carried out following the European request, but an EU spokesman refused to confirm this.

Comments

Comments are closed for this article.